EU/3/10/732: Orphan designation for the treatment of Hodgkin's lymphoma

Entinostat

Table of contents

Overview

On 10 June 2010, orphan designation (EU/3/10/732) was granted by the European Commission to Nexus Oncology Ltd, United Kingdom, for entinostat for the treatment of Hodgkin's lymphoma.

In February 2013, Nexus Oncology Ltd changed name to Ockham Europe Limited.

The sponsorship was transferred to Syndax Limited, United Kingdom, in April 2015.

The sponsorship was transferred to Southwood Research Limited The Netherlands, in February 2019.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

The sponsor's address was updated in June 2021.

The sponsorship was transferred to Propharma Group The Netherlands B.V., Netherlands in April 2022.

Key facts

Active substance
Entinostat
Intended use
Treatment of Hodgkin's lymphoma
Orphan designation status
Positive
EU designation number
EU/3/10/732
Date of designation
10/06/2010
Sponsor

Propharma Group The Netherlands B.V.
Schipholweg 73
2316 ZL Leiden
Zuid-Holland
Netherlands
E-mail: info@propharmagroup.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating